Prolonged Release vs Sustained Release Tablets: A Comprehensive Guide for Pharmaceutical Professionals

Prolonged release and sustained release tablets both belong to the modified release family but differ fundamentally in their pharmacokinetic goals, release kinetics, and clinical positioning. Understanding these differences is essential for formulation scientists, regulatory teams, and plant owners when designing products, planning bioequivalence studies, or drafting CMC documentation.

---

---

Introduction: Modified Release as an Overarching Concept

Modified release (MR) dosage forms deliberately alter the rate, site, or timing of drug release compared with an immediate release (IR) reference product. Major regulatory agencies—including the EMA, FDA, and WHO—classify modified release as a broad category encompassing extended, delayed, sustained, controlled, prolonged, and pulsatile systems [1, 2].

Oral MR tablets and capsules serve three primary clinical objectives:

• Maintaining therapeutic plasma levels over longer dosing intervals
• Reducing administration frequency to improve patient adherence
• Minimising peak-trough fluctuations that drive adverse effects or loss of efficacy [1, 3]

Within this framework, sustained release (SR) and prolonged release (PR) are two related but mechanistically distinct approaches. Conflating them creates problems in regulatory submissions, dissolution method design, bioequivalence strategy, and clinical messaging. This guide draws a clear, evidence-based line between them.

---

What Is Sustained Release (SR)?

Sustained release formulations are engineered to release the active pharmaceutical ingredient (API) gradually over an extended period, maintaining drug concentration within the therapeutic window for the entire dosing interval. By moderating the input rate, SR products approximate a near-steady-state plasma level after each dose, substantially reducing peak-trough fluctuations relative to an equivalent IR regimen [4, 5].

Key Characteristics of Sustained Release Tablets

Primary objective: Maintain a relatively constant plasma concentration over a specified period—typically 8 to 24 hours—often approaching zero-order or near zero-order input kinetics [4].

Release kinetics: Controlled and uniform release rate, frequently engineered to meet pre-defined in vitro–in vivo correlation (IVIVC) targets across physiologically relevant dissolution conditions [3].

Clinical aim: Continuous therapeutic effect with reduced dosing frequency and characteristically fewer peak-related adverse events, particularly relevant for APIs with concentration-dependent toxicity [5, 6].

Plasma profile: Flatter concentration-time curve with demonstrably lower fluctuation index compared with the IR reference at steady state [1].

Sustained Release Technologies

SR systems require tighter engineering to approach a constant release rate across variable gastrointestinal (GI) conditions. Established technologies include:

• Hydrophilic matrix tablets (e.g., hydroxypropyl methylcellulose, HPMC) engineered for controlled swelling and erosion
• Hydrophobic or waxy matrices controlling diffusion through insoluble channels
• Multiparticulate systems—pellets, mini-tablets—with controlled coating thicknesses achieving rate-limiting membrane diffusion
• Osmotic pump tablets (e.g., OROS) with semi-permeable membranes and laser-drilled orifices delivering near zero-order release independent of GI pH [3, 4]

These systems must demonstrate robust, reproducible dissolution across multiple media and agitation conditions, particularly when dissolution profiles are linked to IVIVC claims or biowaivers.

---

What Is Prolonged Release (PR)?

Prolonged release systems extend the duration of drug action beyond that achieved with conventional IR products but do not necessarily maintain a constant plasma concentration profile. The primary objective is to keep drug levels above the minimum effective concentration (MEC) for longer—often enabling once- or twice-daily dosing where IR would require more frequent administration [1, 5].

Key Characteristics of Prolonged Release Tablets

Primary objective: Extend the time the drug remains at clinically effective levels without strictly targeting a flat plasma profile [1].

Release kinetics: Gradual, often first-order–like release, with plasma concentrations that rise more slowly than IR and decline more slowly, but still exhibit more fluctuation than a well-optimised SR profile [4, 5].

Clinical aim: Longer duration of action and improved patient convenience, accepting some variation in plasma concentration provided it remains within acceptable efficacy and safety margins throughout the dosing interval [1, 6].

Plasma profile: Intermediate between IR and SR—lower and later Cmax than IR, extended time above MEC, but without the sustained plateau characteristic of SR designs [3].

Prolonged Release Technologies

PR tablets often use simpler or lower-intensity control mechanisms, prioritising extended release over precision flatness:

• Matrices with slower-dissolving excipients that delay complete release without requiring tight zero-order control
• Coatings that slow disintegration or diffusion but are less tightly tuned than typical SR membrane coatings
• Modified particle size distribution, salt forms, or polymorphs that inherently slow dissolution rate
• Bi-layer tablet designs with an IR loading dose and a PR maintenance component [4, 5]

PR approaches can be commercially attractive in cost-sensitive markets or for APIs with relatively wide therapeutic windows where near-zero-order control is not clinically necessary.

---

Extended Release vs Sustained Release vs Prolonged Release: Clarifying the Terminology

“Extended release” (ER or XR) functions as an umbrella regulatory and marketing term, under which sustained and prolonged release are subtypes. The challenge is that many manufacturers, formularies, and prescribers use ER and SR interchangeably, which can obscure their different design intent and complicate regulatory review [1, 4].

Regulatory Terminology Framework

Term	Scope	Key Design Criterion
Modified release (MR)	Broadest category; any deliberate change in release versus IR	Rate, site, or timing of release altered
Extended release (ER/XR)	Any formulation extending release or action vs IR	Duration longer than IR; profile shape not specified
Sustained release (SR/CR)	Subset of ER targeting near-constant plasma concentration	Reduced fluctuation index; near zero-order input preferred
Prolonged release (PR)	Subset of ER targeting extended time above MEC	Duration above MEC extended; flat profile not required
Controlled release (CR)	Often used interchangeably with SR	Implies precision in rate control
Delayed release (DR)	Separate category; release deferred to a specific site	Enteric coating is the classic example

Source: Adapted from EMA Guideline EMA/CHMP/EWP/280/96 Rev1 [1] and FDA SUPAC-MR guidance [2].

From a Quality by Design (QbD) and regulatory perspective, clearly specifying whether a product claims controlled/sustained release (reduced fluctuation) versus prolonged release (extended duration above MEC) helps define release specifications, dissolution profile targets, and bioequivalence study endpoints [1, 2].

---

Prolonged Release vs Sustained Release Tablets: Key Differences

The table below consolidates practical, kinetic, and formulation distinctions that matter for development and regulatory submissions.

Comprehensive Comparison Table

Parameter	Sustained Release (SR)	Prolonged Release (PR)
Primary objective	Maintain near-constant plasma concentration over set dosing interval	Extend duration of effect beyond IR; stay above MEC
Release rate	Controlled; often zero-order or pre-defined profile	Gradual; typically first-order–like; less uniform
Plasma concentration pattern	Flatter profile; reduced Cmax; lower trough fluctuation	Slower rise and fall vs IR; more fluctuation than SR
Fluctuation index target	Explicitly minimised; often a regulatory endpoint	Acceptable within defined safety/efficacy margins
Dosing frequency	Often once daily for drugs requiring multiple IR doses	Reduces frequency vs IR; may not match well-optimised SR
Typical technologies	HPMC matrices, osmotic pumps, multiparticulates, multi-layer tablets	Slower-dissolving matrices, delayed-disintegration coatings, modified salts
IVIVC rigour	High; often required for biowaivers and scale-up flexibility	Moderate; broader dissolution windows typically acceptable
Risk of dose dumping	High regulatory scrutiny; robust in vitro controls mandatory	Still scrutinised; less aggressive “flat-profile” dissolution targets
Bioequivalence endpoints	AUC, Cmax, Cτ, fluctuation index, partial AUCs	AUC, Cmax; duration above MEC often primary clinical evidence
Regulatory burden	Higher; must demonstrate reduced fluctuation vs IR	Lower; adequate exposure and duration above MEC typically sufficient
Manufacturing complexity	Higher; tight process controls on coating, matrix formation	Moderate; fewer critical parameters for flat-profile maintenance
Clinical messaging	“Steady 24-hour control” / “reduced peak-trough swings”	“Long-lasting relief” / “extended once-daily action”
Typical indications	Hypertension, epilepsy, angina, diabetes, psychiatric disorders	Chronic pain, musculoskeletal conditions, convenience formulations

Data reflect descriptions from pharmaceutics references and regulatory guidance on modified release characteristics [1–5].

---

Pharmacokinetics: Concentration–Time Behaviour

Understanding the pharmacokinetic (PK) profile distinguishing IR, SR, and PR is fundamental to formulation decision-making and regulatory communication.

Immediate Release Baseline

In a conventional IR tablet, most of the dose is absorbed rapidly in the upper GI tract, producing a sharp peak (Cmax) followed by rapid decline. This creates marked fluctuations throughout the day, with plasma levels potentially exceeding toxic thresholds near Tmax and falling below the MEC before the next dose [3, 5].

Sustained Release PK Profile

SR systems reshape the input function to approximate a rate-in equal to rate-out steady state:

• Slower rise: Cmax lower and Tmax later than IR
• Extended plateau: Drug levels maintained within the therapeutic window for most of the dosing interval
• Smoother decline: Concentration at end of dosing interval (Cτ) substantially higher than IR trough
• Fluctuation index: Defined as (Cmax − Cmin) / Cavg; SR products characteristically achieve a lower index than IR at steady state [1, 4]

Prolonged Release PK Profile

PR produces an intermediate curve:

• Delayed absorption: Rise slower than IR but faster than SR
• Lower Cmax: Peak reduced relative to IR but not as flat as SR
• Extended time above MEC: Drug remains clinically active longer than IR
• More variable Cτ: End-of-interval concentration may be lower than SR but still above MEC [3, 5]

Key PK Parameters for Regulatory Comparison

Regulators increasingly emphasise parameters beyond basic AUC and Cmax when evaluating MR versus IR comparisons [1]:

• Cτ (trough concentration): Confirms therapeutic coverage at end of dosing interval
• Cmin (minimum concentration at steady state): Verifies no subtherapeutic troughs
• Partial AUC: Captures early and late exposure within the dosing interval; used when front-loading or tail exposure is clinically meaningful
• Fluctuation index: Quantifies peak-trough variation relative to average concentration
• Peak-trough ratio: Simpler metric for fluctuation; higher values indicate more variable exposure

---

Regulatory Perspectives on Prolonged and Sustained Release

Major regulatory bodies do not always draw a sharp legal line between SR and PR, but they are precise about the broader MR concept and require dossier language to match demonstrated PK behaviour [1, 2].

EMA Guidance

The EMA Guideline on Pharmacokinetic and Clinical Evaluation of Modified Release Dosage Forms (EMA/CHMP/EWP/280/96 Rev1, 2019) sets out study designs, PK endpoints, and clinical rationale for MR formulations across oral, parenteral, and transdermal routes. The guideline requires that products labelled as sustaining or controlling plasma levels provide data demonstrating reduced fluctuation compared with IR at steady state [1].

The EMA Guideline on Quality of Oral Modified Release Products additionally specifies dissolution testing requirements, release specifications, and considerations for patient manipulation of tablets (e.g., risk of splitting prolonged release tablets and altering the release mechanism) [7].

FDA Guidance

FDA’s SUPAC-MR guidance addresses post-approval changes for MR solid oral dosage forms and identifies release-controlling excipients as critical quality attributes. It emphasises the need for validated, discriminatory dissolution methods that are stability-indicating and capable of detecting changes that would alter in vivo performance [2].

The guidance also establishes a tiered system for post-approval change levels (Levels 1–3), with corresponding dissolution and bioequivalence testing requirements depending on the magnitude of change. For SR products with established IVIVC, Level 2 and Level 3 changes may be addressed via dissolution data alone, providing significant regulatory flexibility [2].

Implications for SR vs PR Dossier Positioning

If a label or promotional material claims “controlled/sustained release” with reduced fluctuation, regulators expect data demonstrating a measurably smoother PK profile versus IR at steady state. For products framed as “prolonged” or “extended-action,” the primary burden is to demonstrate acceptable total exposure, adequate duration above MEC, and an acceptable safety profile—without necessarily proving near-constant plasma levels [1, 2].

For markets operating under ICH and EMA guidance—including WHO-GMP and USFDA-oriented facilities in South Asia—dossier terminology must align with actual PK behaviour and dissolution data to avoid misalignment during regulatory review or inspection [1, 2, 8].

---

Formulation Strategies for SR vs PR Tablets

Sustained Release: Formulation Design Focus

SR tablets require precise engineering to approach a constant release rate across variable GI conditions, including pH changes from stomach to colon, transit time variability, and food-effect perturbations. Key formulation principles include:

Matrix system design:

• HPMC concentration and viscosity grade determine gel layer thickness and diffusion path length; higher viscosity grades slow release
• Hydrophobic polymers (e.g., ethylcellulose, Eudragit RS/RL) control diffusion rather than erosion, providing more pH-independent release
• Combination matrices using both hydrophilic and hydrophobic components can fine-tune the release profile

Membrane-coated systems:

• Coating weight gain and pore-former concentration are critical process parameters (CPPs) that directly govern release rate
• Aqueous coating processes require careful control of spray rate, inlet air temperature, and bed temperature to ensure film integrity
• Multiparticulate systems distribute dose across hundreds of units, reducing dose-dumping risk from single-unit failure

Osmotic systems:

• Zero-order delivery largely independent of GI pH and motility; ideal for highly pH-sensitive APIs
• Orifice diameter and semi-permeable membrane thickness are primary design levers
• Require more complex manufacturing infrastructure and higher cost [3, 4]

Prolonged Release: Formulation Design Focus

PR tablets use less tightly controlled mechanisms, prioritising extended duration over precise flatness:

• Matrices with moderate polymer concentrations that delay but do not fully control dissolution
• Wax-based or fat-based matrices that melt at body temperature, providing gradual release without sophisticated coating
• Modified disintegrants or super-disintegrant exclusion strategies that slow tablet breakdown without a true matrix
• Lower-intensity coating strategies where film thickness is intentionally less uniform [4, 5]

Pre-formulation Considerations Applicable to Both

BCS classification: APIs in BCS Class I (high solubility, high permeability) and Class II (low solubility, high permeability) are most amenable to MR formulation. Class III and IV APIs require additional permeation strategies that may conflict with controlled release objectives [3].

Half-life: An API with a very long intrinsic half-life may not benefit significantly from MR formulation. SR and PR are most impactful for APIs with half-lives of 2–8 hours, where the release rate from the dosage form becomes rate-limiting [4, 5].

Therapeutic window: APIs with narrow therapeutic windows are candidates for SR to minimise both toxic peaks and subtherapeutic troughs. Wider therapeutic windows support PR approaches where some fluctuation is acceptable [1].

Food effect: High-fat meals can significantly alter the GI environment and potentially cause dose dumping from fat-soluble matrices. Pre-formulation food-effect assessment is mandatory for both SR and PR development [1, 2].

---

Clinical and Patient-Centric Considerations

Both SR and PR aim to improve adherence and clinical outcomes compared with IR dosing schedules, but the optimal approach depends on the disease, API pharmacology, and safety profile.

Shared Benefits

Sustained and prolonged release formulations share the following advantages over IR regimens:

• Reduced dosing frequency: Once- or twice-daily administration versus 3–6 daily doses of IR forms significantly improves adherence, which correlates with improved clinical outcomes in chronic disease management [6]
• Smoother symptom control: Fewer “wear-off” episodes during the trough period; particularly important in conditions where symptom breakthrough is distressing (chronic pain, Parkinson’s disease, epilepsy)
• Potential reduction in peak-related adverse events: Lower Cmax reduces concentration-dependent adverse effects; most pronounced with SR designs where peak reduction is greater [5, 6]

Trade-offs and Risks

Manufacturing complexity: SR and PR manufacturing requires validated coating and matrix processes, controlled excipient specifications, and more extensive dissolution testing programmes than IR manufacturing.

Dose-dumping risk: Mechanical failure of a matrix or coating system—or co-ingestion with alcohol—can result in rapid release of the entire dose. This is particularly hazardous for opioids and other APIs with narrow safety margins. Regulatory agencies require specific dose-dumping studies for MR products in the presence of alcohol [1, 2].

Dose individualisation challenges: MR tablets and capsules typically cannot be split, chewed, or crushed without destroying the release mechanism. This limits dose flexibility for paediatric patients or those requiring intermediate doses [7].

GI motility dependence: Prolonged GI transit time (e.g., in constipation) or accelerated transit (e.g., in diarrhoea or short bowel syndrome) can alter drug release and absorption from both SR and PR systems in ways that are difficult to predict or control [3].

Indication-Specific Considerations

Conditions favouring SR:

• Hypertension: tight 24-hour blood pressure control; reduced morning surge risk
• Epilepsy: consistent seizure threshold maintenance; fluctuation-driven breakthrough seizures
• Type 2 diabetes: stable glycaemic control throughout the day
• Psychiatric disorders: reduced peak-related sedation or activation while maintaining efficacy [6]

Conditions where PR may be sufficient:

• Musculoskeletal pain: extended analgesia with acceptable trough; convenience primary driver
• Overactive bladder: consistent receptor occupancy; therapeutic window typically wide
• Non-critical chronic conditions where adherence improvement is the primary goal [5]

---

In Vitro Dissolution and IVIVC

Why Dissolution Method Design Differs for SR and PR

The dissolution method must be discriminatory—capable of detecting formulation changes that would alter in vivo performance—and ideally predictive of in vivo release when a valid IVIVC exists.

For SR formulations targeting zero-order release, multi-timepoint dissolution specifications are typically tighter (e.g., 20–30% at 2 h; 50–60% at 6 h; NLT 80% at 12 h) and must be demonstrated in at least three pH conditions to ensure GI robustness [1, 2].

For PR formulations with first-order–like release, dissolution windows may be somewhat broader, reflecting the less stringent flat-profile requirement, though regulatory guidance still mandates discriminatory methods that would detect changes expected to affect clinical performance [2].

IVIVC Levels

IVIVC is classified into three levels, with Level A being the most informative and commercially valuable [2]:

IVIVC Level	Definition	Value for MR Products
Level A	Point-to-point relationship between in vitro dissolution and in vivo absorption rate	Supports biowaivers for certain post-approval changes; most commercially valuable
Level B	Mean dissolution time vs mean in vivo residence time	Does not support biowaivers; limited regulatory utility
Level C	Single dissolution time point vs single PK parameter	Least informative; useful only for early development

Level A IVIVC is most achievable for SR formulations with tight dissolution control. For PR products, Level C or B correlations may be acceptable in early development but are insufficient for post-approval change biowaivers [1, 2].

---

Development and Validation: What Changes Between SR and PR?

Pre-formulation and Biopharmaceutics

Pre-formulation studies for both SR and PR must characterise:

• API solubility as a function of pH (1.2 to 6.8) and temperature
• Intrinsic dissolution rate and particle size sensitivity
• Permeability class (BCS classification; Caco-2 or in situ intestinal perfusion studies)
• Half-life, volume of distribution, and predicted plasma profile requirements
• Food-effect potential and interaction with GI lipids or bile salts [3, 4]

For SR specifically: APIs with short half-lives (2–6 hours) and narrow therapeutic windows derive the greatest clinical benefit from SR, because controlled input materially reduces peak-trough fluctuation. Emphasis is placed on achieving a pre-defined input rate matching the desired plasma plateau throughout the dosing interval.

For PR specifically: Half-life and therapeutic window matter, but the emphasis shifts to ensuring extended time above MEC with acceptable safety margins rather than plateau precision. APIs with moderate half-lives (4–12 hours) and wider therapeutic windows are good PR candidates.

Validation Requirements

Dissolution method validation: Both SR and PR methods must be validated for specificity, linearity, precision, accuracy, robustness, and stability. For MR products, discriminatory power against formulation variables (polymer grade, coating weight, compression force) is an additional validation requirement [2].

Process validation: SR manufacturing typically involves more CPPs than PR, requiring tighter process characterisation and potentially more extensive process analytical technology (PAT) implementation to ensure batch-to-batch consistency in release-controlling attributes.

Stability testing: MR tablets require stability studies demonstrating that the release mechanism is maintained throughout shelf life under ICH conditions. Dissolution profile comparison at initial and end-of-shelf-life timepoints using f2 similarity factor (f2 ≥ 50) is standard practice [1, 2].

---

When to Choose Prolonged vs Sustained Release for a New Product

Decision Framework

Formulation and business decisions must balance technical feasibility, regulatory expectations, market positioning, and commercial return.

Decision Criterion	Favour Sustained Release (SR)	Favour Prolonged Release (PR)
API half-life	Short (2–6 hours)	Moderate (4–12 hours)
Therapeutic window	Narrow; fluctuation clinically significant	Wider; some fluctuation acceptable
Clinical indication	Conditions requiring tight control (BP, seizures)	Convenience-driven; symptom-duration focus
Regulatory market	Premium USFDA/EMA markets with robust PK expectations	Emerging markets; lifecycle management
Manufacturing capability	Osmotic, coated multiparticulate, complex matrix infrastructure	Standard matrix; moderate coating capability
Development investment	Higher; justified by premium positioning	Lower; faster to market
IVIVC expectation	Typically required for flexibility	Optional; Level C may be acceptable
Competition differentiation	“Better control” vs originator IR	“Once-daily convenience” vs originator IR

Decision criteria based on regulatory guidance and pharmaceutical development principles [1–5].

Internal Alignment: A Common Failure Point

A frequently overlooked risk in MR product development is the misalignment between R&D’s formulation intent, regulatory’s labelling strategy, and marketing’s product claims. Clearly defining internal terminology at project initiation—”PR convenience product” versus “SR control product”—prevents downstream conflicts in dossier writing, CMC documentation, and promotional material review.

---

Common Mistakes in SR and PR Development

Recognising common errors early can prevent costly late-stage failures:

1. Mislabelling the product type in early development: Calling a first-order release product “sustained release” sets incorrect PK expectations and dissolution targets, leading to failing bioequivalence studies.

2. Inadequate dissolution method development: Using a single pH or non-discriminatory agitation condition that fails to detect formulation changes predictive of altered in vivo performance. SUPAC-MR requires dissolution testing in at least three different media [2].

3. Ignoring food effect: Fatty meals can alter GI motility, pH, and solubilisation capacity, fundamentally changing release from matrix and coated systems. Omitting food-effect studies until Phase III is a high-risk strategy.

4. Underestimating dose-dumping risk: Single-unit formulations (as opposed to multiparticulates) that release full dose rapidly when the release mechanism fails. Alcohol-induced dose dumping has been implicated in serious adverse events with opioid MR products; FDA now requires specific alcohol-dose-dumping studies for certain drug classes [2].

5. Selecting the wrong API for MR formulation: APIs with very long half-lives (>24 hours), very poor aqueous solubility (BCS Class IV), or highly variable absorption (BCS Class III, poorly permeable) are poor candidates for conventional MR technologies.

6. Insufficient scale-up data: Coating and matrix processes that perform well at laboratory scale often fail at commercial scale due to equipment geometry changes, spray dynamics, and drying air volume differences. SUPAC-MR Level 3 site or scale changes require in vivo bioequivalence unless an established IVIVC exists [2].

---

Best Practices for Formulation and Regulatory Teams

For formulation scientists:

Apply QbD principles from project initiation. Define the target product profile (TPP) and target product quality profile (TQPP) before selecting the release mechanism. Identify critical quality attributes (CQAs)—particularly dissolution rate and release mechanism integrity—and critical process parameters (CPPs) through risk assessment (ICH Q9) and Design of Experiments (DoE) [9].

Use multivariate dissolution profiling across pH 1.2, 4.5, and 6.8 to build robustness data and support IVIVC development early in the project.

For regulatory scientists:

Align product labelling with demonstrated PK behaviour before filing. Ensure dissolution specifications are discriminatory and that the justification for the chosen release rate is scientifically sound and cross-referenced to PK data.

Reference EMA/CHMP/EWP/280/96 Rev1 [1] for clinical evaluation requirements and FDA SUPAC-MR [2] for post-approval change management. For WHO-GMP markets, align with TGA and WHO technical guidance where applicable [8].

For plant owners and CMC teams:

Validate coating processes with design space data rather than point estimates. Document the relationship between inlet air temperature, spray rate, and coating weight gain with their effects on dissolution at commercial scale.

Maintain a dissolution lifecycle management plan that addresses potential post-approval changes—including excipient supplier changes, equipment changes, and batch size scale-up—with pre-assessed SUPAC-MR change levels and corresponding testing requirements [2].

For quality assurance teams:

Implement real-time dissolution monitoring where possible, particularly for osmotic and membrane-coated products where coating defects may not be visually detectable. Stability-indicating dissolution methods should be routinely applied to retain samples from each production batch to enable trending and early detection of release-profile drift.

---

How Laafon Galaxy can support SR/PR initiatives?

If you are planning an SR or PR project, aligning formulation strategy with plant capabilities and regulatory expectations early can save significant time and cost in development and validation.
Through Laafon.com, you can explore pharma manufacturing plants for sale that are suitable for MR technologies and request consultations on facility readiness, QbD documentation, and scale‑up planning tailored to USFDA/WHO‑GMP markets.

FAQ

---

References

1. European Medicines Agency (EMA). Guideline on the pharmacokinetic and clinical evaluation of modified release dosage forms. EMA/CHMP/EWP/280/96 Rev1. London: EMA; 2019. Available from: https://www.ema.europa.eu/en/pharmacokinetic-clinical-evaluation-modified-release-dosage-forms-scientific-guideline
2. U.S. Food and Drug Administration (FDA). SUPAC-MR: Modified Release Solid Oral Dosage Forms: Scale-Up and Postapproval Changes—Chemistry, Manufacturing, and Controls; In Vitro Dissolution Testing and In Vivo Bioequivalence Documentation. Rockville: FDA; 1997. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/supac-mr-modified-release-solid-oral-dosage-forms-scale-and-postapproval-changes
3. Siepmann J, Siepmann F. Mathematical modeling of drug release from lipid dosage forms. Int J Pharm. 2011;418(1):42–53.
4. Khan MA, Özalp Y. Sustained Drug Release [Internet]. ScienceDirect Topics. Amsterdam: Elsevier; 2023. Available from: https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/sustained-drug-release
5. Stahl SM. Sustained-release, extended-release, and other time-release formulations in neuropsychiatry. J Clin Psychiatry. 2008;69(12):1901–9. Available from: https://www.psychiatrist.com/jcp/sustained-release-extended-release-release-formulations/
6. Langer R. Drug delivery and targeting. Nature. 1998;392(6679 Suppl):5–10.
7. European Medicines Agency (EMA). Guideline on quality of oral modified release products. London: EMA; 2014. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-quality-oral-modified-release-products_en.pdf
8. Therapeutic Goods Administration (TGA), Australia. Guideline on the pharmacokinetic and clinical evaluation of modified release dosage forms [Internet]. Canberra: TGA; 2019. Available from: https://www.tga.gov.au/resources/resources/international-scientific-guidelines-adopted-australia/guideline-pharmacokinetic-and-clinical-evaluation-modified-release-dosage-forms
9. International Council for Harmonisation (ICH). ICH Q9(R1): Quality Risk Management. Geneva: ICH; 2023. Available from: https://www.ich.org/page/quality-guidelines
10. Khan R, Patel P, Patel M. Formulation and evaluation of sustained release matrix tablets of rabeprazole. J Adv Pharm Technol Res. 2014;5(2):92–6. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC4097931/
11. U.S. Food and Drug Administration (FDA). SUPAC-MR full PDF guidance document. Rockville: FDA; 1997. Available from: https://www.fda.gov/media/70956/download
12. Accessible Medicines. Scale Up and Post Approval Changes (SUPAC) Guidance: GRx+Biosims 2024 presentation. Washington DC: Accessible Medicines; 2024. Available from: https://accessiblemeds.org/wp-content/uploads/2024/12/GRxBiosims-2024-PPT-David-Awotwe-Otoo.pdf
13. Research Journal of Pharmacy and Technology. Sustained release products: a review on formulation and evaluation. Res J Pharm Technol. 2013;6(12). Available from: https://rjptonline.org/HTMLPaper.aspx?Journal=Research+Journal+of+Pharmacy+and+Technology%3BPID%3D2013-6-12-13
14. International Journal of Pharmaceutical Research and Applications. Sustained release drug delivery system: a review. Int J Pharm Res Appl. 2021. Available from: https://ijprajournal.com/issue_dcp/Sustained%20Release%20Drug%20Delivery%20System%20%20A%20Review.pdf
15. U.S. Food and Drug Administration (FDA). SUPAC-IR: Immediate-Release Solid Oral Dosage Forms: Scale-Up and Postapproval Changes. Rockville: FDA; 1995. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/supac-ir-immediate-release-solid-oral-dosage-forms-scale-and-postapproval-changes

See youtube Video: Prolonged Release vs Sustained Release Tablets